Table 2.
Characteristics of the general population cohort and of the cohort of patients who died from COVID-19
| Neutralization 100 pg/mL | Neutralization 10 ng/mL | |||
|---|---|---|---|---|
| Characteristics | General population (n = 10,778) | Deceased patients (n = 1,121) | General population (n = 34,159) | Deceased patients (n = 1,094) |
| Male – no. (percent) | 5,429 (50.4)* | 821 (73.2) | 17,859 (52.3) | 805 (73.5) |
| Mean age ± SD* – years | 62.3 ± 17.2 | 70.7 ± 13.0 | 52.7 ± 18.2 | 70.6 ± 13.1 |
| Age distribution – no. (percent) | ||||
| 20 y to 39 y | 1,251 (11.6) | 17 (1.5) | 9,102 (26.6) | 15 (1.4) |
| 40 y to 49 y | 1,459 (13.5) | 43 (3.8) | 5,403 (15.8) | 47 (4.3) |
| 50 y to 59 y | 1,736 (16.1) | 144 (12.8) | 6,414 (18.9) | 152 (13.9) |
| 60 y to 69 y | 2,475 (23.0) | 307 (27.4) | 6,881 (20.1) | 289 (26.4) |
| 70 y to 79 y | 1,790 (16.6) | 307 (27.4) | 3,721 (10.9) | 296 (27.1) |
| ≥80 y | 2,067 (19.2) | 303 (27.0) | 2,638 (7.7) | 295 (27.0) |
| Auto-Ab – no. of carriers (percent) | ||||
| IFN-α2 and IFN-ω | 65 (0.6) | 102 (9.1) | 45 (0.1) | 75 (6.8) |
| IFN-α2 or IFN-ω | 246 (2.3) | 203 (18.1) | 181 (0.5) | 130 (11.9) |
| IFN-α2 | 151 (1.4) | 140 (12.5) | 117 (0.3) | 118 (10.8) |
| IFN-ω | 160 (1.5) | 165 (14.7) | 109 (0.3) | 87 (8.0) |
| IFN-β† | NA | NA | 24 (0.3) | 6 (0.9) |
NA, not available.
*Age is given in years and corresponds to age at the time of recruitment for members of the general population cohort (controls) and age at death for COVID-19 patients.
†IFN-β neutralization experiments were performed only for a concentration of 10 ng/mL, on 9,126 individuals (49.5% male, mean age 60.6 y) from the general population and 636 COVID-19 patients (71.1% male, mean age 72.9 y).